The Health Policy Podcast explores how healthcare policy decisions impact patients, providers, costs, and innovation across the U.S. healthcare system. Through interviews with physicians, policy experts, researchers, and industry leaders, the podcast examines the real-world effects of laws, regulations, and market forces shaping healthcare today.
The Preventable Peptide Crisis: Navigating GLP-1s and the Gray Market
In this episode of the Health Policy Podcast, host Brian Hyde speaks with Peter Pitts, former FDA Associate Commissioner and President of the Center for Medicine in the Public Interest. They discuss the growing popularity of GLP-1 weight loss drugs and the critical issues surrounding their use. Pitts emphasizes that while GLP-1s can be effective, they are not a "magic pill" and should be used under medical supervision, alongside diet and exercise, and not for chronic conditions without further research. The conversation highlights the serious dangers posed by counterfeit and unapproved GLP-1s sold online, stressing the lack of quality control and the potential for severe health consequences, including hospitalization and death. Pitts advocates for increased FDA enforcement against these criminal enterprises and advises consumers on how to avoid falling victim to illicit suppliers, emphasizing the importance of FDA approval and doctor consultation.
6 Oct 2026
Beyond Politics: A New Era in Global Health Strategy
Dr. Alma Golden, pediatrician and former Assistant Administrator for Global Health at USAID, discusses the evolution of global health strategy on the Health Policy Podcast. She highlights a shift from previous approaches—often characterized by funding tied to specific mandates through NGOs—to the "America First" strategy's emphasis on bilateral agreements, country-led priorities, and whole-person care.
Dr. Golden explains the origins and impact of the Geneva Consensus Declaration, an agreement among now 41 nations promoting national sovereignty in healthcare decisions and rejecting the idea of abortion as an international right. She elaborates on how this new approach fosters trust, supports faith-based organizations, and recognizes the pivotal role of family in health outcomes, advocating for treating nations as partners rather than projects.
1 Oct 2026
Drug Prices: The Real Cost of Government Intervention
In this episode of the Health Policy Podcast, host Brian Hyde speaks with Eric Moss, Director of Health and Science Policy at Citizens Against Government Waste. They delve into the complex landscape of prescription drug pricing in America, discussing how federal programs like 340B and provisions within the Inflation Reduction Act (IRA) have impacted costs and access. Moss reveals that despite initial projections of savings, the IRA's drug pricing controls are now estimated to cost $700 billion, driving up monthly drug costs for seniors. The conversation also explores the historical ineffectiveness of price controls and the benefits of a free-market approach for pharmaceutical innovation. Additionally, Moss highlights a bipartisan effort to modernize outdated FDA regulations for prescribing information, moving from paper-based delivery to electronic, which promises significant savings and improved efficiency for healthcare providers.
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
4 ratings
Contact Health Policy Podcast
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine
